Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration's Mini-Sentinel program
Authors
Andrade, Susan E.Reichman, Marsha
Mott, Katrina
Pitts, Marilyn
Kieswetter, Caren
Dinatale, Miriam
Stone, Marc B.
Popovic, Jennifer
Haffenreffer, Katherine
Toh, Sengwee
Document Type
Journal ArticlePublication Date
2016-12-01Keywords
PregnancyPrevalence
Selective serotonin reuptake inhibitors
Maternal and Child Health
Psychiatry and Psychology
Women's Health
Metadata
Show full item recordAbstract
This study was conducted in order to assess the prevalence of use of selective serotonin reuptake inhibitors (SSRIs) among pregnant women delivering a liveborn infant in the USA. A retrospective study was conducted using the automated databases of 15 health-care systems participating in the Mini-Sentinel program. Diagnosis and procedure codes were used to identify women ages 10 to 54 years delivering a liveborn infant between April 2001 and December 2013. A comparison group of age- and date-matched women without live births was identified. The frequency of use of SSRIs was identified from outpatient dispensing data. Among the 1,895,519 liveborn deliveries, 113,689 women (6.0 %) were exposed to an SSRI during pregnancy during the period 2001-2013; 5.4 % were exposed to an SSRI during 2013. During the corresponding time period, 10.5 % of the age- and date-matched cohort of women without live births was exposed to an SSRI, with 10.1 % exposed to an SSRI during 2013. The most common agents dispensed during pregnancy were sertraline (n = 48,678), fluoxetine (n = 28,983), and citalopram (n = 20,591). Among those women exposed to an SSRI during pregnancy, 53.8 % had a diagnosis of depression and 37.3 % had a diagnosis of an anxiety disorder during pregnancy or within 180 days prior to pregnancy. Our finding that 6 % of women with live births were prescribed SSRIs during pregnancy highlights the importance of understanding the differential effects of these medications and other therapeutic options on the developing fetus and on the pregnant women.Source
Arch Womens Ment Health. 2016 Dec;19(6):969-977. Epub 2016 May 13. Link to article on publisher's siteDOI
10.1007/s00737-016-0637-1Permanent Link to this Item
http://hdl.handle.net/20.500.14038/28874PubMed ID
27178125Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1007/s00737-016-0637-1